Omega 3 Polyunsaturated Fatty Acids (PUFA) or Magnesium in Obese Polycystic Ovary Syndrome Patients
Status:
Suspended
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Polycystic ovary syndrome (PCOS) is the most prevalent endocrine disorder in reproductive age
women. PCOS is usually characterized by an excessive androgen production, menstrual
irregularities, and polycystic ovaries. Women with PCOS are often obese and have a varying
degree of insulin resistance (IR). Weight reduction constitutes the initial treatment for
these patients. Metformin has proven to be useful in IR and is frequently used in PCOS.
However metformin use may be accompanied by gastrointestinal discomfort, and a high abandon
rate. Other therapeutic alternatives such as magnesium and polyunsaturated fatty acids have
been used in other IR states and may be useful in PCOS. The aim of this study is to asses the
efficacy of these alternatives in obese PCOS patients.